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Deficiency of AXL in Bone Marrow-
Derived Cells Does Not Affect 
Advanced Atherosclerotic Lesion 
Progression
Manikandan Subramanian1,2,*, Jonathan D. Proto1,*, Glenn K. Matsushima3 & Ira Tabas1,4,5
AXL, a member of the TAM (Tyro3, Axl, MerTK) family of receptors, plays important roles in cell 
survival, clearance of dead cells (efferocytosis), and suppression of inflammation, which are processes 
that critically influence atherosclerosis progression. Whereas MerTK deficiency promotes defective 
efferocytosis, inflammation, and plaque necrosis in advanced murine atherosclerosis, the role of Axl in 
advanced atherosclerosis progression is not known. Towards this end, bone marrow cells from Axl−/− or 
wild-type mice were transplanted into lethally irradiated Ldlr−/− mice. These chimeric mice were then 
fed the Western-type diet (WD) for 17 weeks. We demonstrate that lesional macrophages in WT mice 
express Axl but that Axl deficiency in bone marrow-derived cells does not affect lesion size, cellularity, 
necrosis, or inflammatory parameters in advanced atherosclerotic plaques. Moreover, apoptosis of 
lesional cells was unaffected, and we found no evidence of defective lesional efferocytosis. In contrast to 
previously reported findings with MerTK deficiency, hematopoietic cell-Axl deficiency in WD-fed Ldlr−/− 
mice does not affect the progression of advanced atherosclerosis or lesional processes associated with 
TAM receptor signaling. These findings suggest a heretofore unappreciated TAM receptor hierarchy in 
advanced atherosclerosis.
Atherosclerosis is a chronic inflammatory disease of the vascular wall induced by apoB-containing lipoproteins 
deposited beneath the endothelium of large and medium-sized arteries1. While the vast majority of atheroscle-
rotic lesions remain clinically silent, a small proportion undergo plaque rupture or erosion, which can precipitate 
acute thrombotic vascular occlusion and its consequences, e.g., myocardial infarction, unstable angina, sudden 
cardiac death, and stroke2,3. Thus, the molecular mechanisms involved in the conversion of benign to vulnerable 
plaques is an area of immense importance. Previous studies have implicated chronic non-resolving inflammation, 
lesional cell apoptosis, defective efferocytosis, plaque necrosis, and thinning of the fibrous cap as critical factors 
influencing this transition2,3.
The TAM family of receptors are increasingly being recognized to play a critical role in tempering inflamma-
tion in several chronic inflammatory as well as autoimmune disorders4. Signaling through these receptors has 
been shown to increase cell survival and promote efferocytosis with consequent generation of anti-inflammatory 
cytokine mediators4. Moreover, MerTK triggers an inflammation resolution signaling pathway in macrophages5. 
We and others have previously shown a critical role for MerTK, which is expressed primarily on macrophages, in 
promoting efferocytosis and suppressing inflammation in advanced atherosclerosis, with a net effect of preventing 
the expansion of necrotic areas in lesions6,7. However, the role of Axl, the other major TAM family member, in 
atherosclerosis progression is not known. In this context, a recent study demonstrated that treatment of cultured 
macrophages with inducers of inflammation is associated with an increase in Axl expression concomitant with 
a decrease in MerTK expression8. These data raise the possibility that Axl signaling may play a dominant role in 
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efferocytosis and suppression of inflammation in pro-inflammatory environments such as that seen in advanced 
atherosclerotic plaques.
To examine this issue, we transplanted bone marrow cells from Axl−/− mice into lethally irradiated Ldlr−/− 
mice to generate chimeric mice that are deficient in Axl in all hematopoietic-derived cells including atheroscle-
rotic lesional macrophages and dendritic cells. In this model, we demonstrate that lesional cells in wild-type mice 
express Axl but that deficiency of Axl does not affect atherosclerotic lesion size, lesional cell apoptosis, efferocy-
tosis, plaque necrosis, inflammation, or fibrosis. These data suggest that Axl in bone marrow-derived cells does 
not play a significant role in advanced atherosclerotic plaque progression, which, in view of the important role of 
MerTK in plaque progression, indicates a fascinating TAM receptor hierarchy in advanced atherosclerosis.
Results
To study the role of Axl in bone marrow-derived cells in advanced atherosclerosis, we generated chimeric mice 
by transplanting Axl−/− bone marrow cells into lethally irradiated Ldlr−/− mice. All mice were on the C57BL/6 J 
background, and control mice received bone marrow from wild-type littermates. Six weeks after transplan-
tation, the mice were fed the Western-type diet for an additional 17 weeks. The two groups of mice gained 
weight equally and had similar metabolic parameters including plasma cholesterol, fasting blood glucose, and 
insulin (Supplementary Figure IA–D) and similar immune cell subset distribution in the peripheral blood 
(Supplementary Figure IE). We confirmed the successful repopulation of donor cells in the recipient mice by 
observing the loss of Axl expression in splenic dendritic cells of mice receiving bone marrows from Axl−/− donors 
(Supplementary Figure IF). We first asked whether Axl was expressed in the aortic root lesional cells of the control 
group and, if so, whether this expression was successfully suppressed in the lesions of the chimeric mice. Indeed, 
Axl immunostaining was clearly evident in the control lesions but not in the Axl−/− → Ldlr−/− lesions, and the 
pattern of expression was similar to that of F4/80+ macrophages (Supplementary Figure IG). These data are con-
sistent with the recent finding that Axl expression is induced in cultured macrophages under inflammatory condi-
tions8. We next quantified the overall lesion area and necrotic area of the aortic root plaques of WT → Ldlr−/− and 
Axl−/− → Ldlr−/− mice and found no statistical difference between the two groups (Fig. 1A–C). Moreover, the per-
cent distribution of lesional macrophages, dendritic cells, and smooth muscle cells was similar between the two 
groups of mice (Fig. 1D). A previous study demonstrated that deficiency of Gas6, which is a ligand that signals 
via the TAM family of receptors, was associated with increased collagen deposition and a more stable plaque9. 
However, hematopoietic cell-Axl deficiency did not result in significant differences in intimal collagen content or 
fibrous cap thickness (Fig. 1E).
In view of the pro-survival role of Axl signaling in several cell types, we analyzed whether deficiency of Axl 
increases lesional cell apoptosis. As demonstrated in Fig. 2A, the extent of TUNEL staining, a reliable meas-
ure of apoptosis in atherosclerotic lesions, was similar between control and hematopoietic cell -Axl deficient 
mice. Similar data was obtained with analysis of expression of cleaved caspase-3, another marker for apoptotic 
cells (Supplementary Figure II). Furthermore, Axl is a known efferocytosis receptor in macrophages and den-
dritic cells8,10, but there was no significant difference in the in-situ efferocytic index of WT → Ldlr−/− versus 
Axl−/− → Ldlr−/− lesions (Fig. 2B and Supplementary Figure III). Because lesional cell apoptosis coupled to 
defective efferocytosis contributes to necrotic core formation3, these data are consistent with the similar lesional 
necrotic area between the two groups of mice.
Axl-Gas6 signaling is known to elicit an anti-inflammatory response in innate immune cells via activation of 
SOCS family of proteins11. Thus, we tested whether expression of pro-inflammatory markers was increased in the 
atherosclerotic lesions of hematopoietic cell -Axl deficient mice. Consistent with all of the lesional data thus far, 
the expression levels of Tnf, Il6, Il12, Ifng, Mcp1, and Il23 was similar between the two groups of mice (Fig. 2C). 
We then turned our attention to T cells, because activated effector T cells promote atherosclerosis progression, 
and T cell-derived Protein S acts on TAM receptors on dendritic cells to dampen the magnitude of the T cell 
response12. However, we did not observe changes in the levels of effector T cells in the spleens of Axl−/− → Ldlr−/− 
mice (Supplementary Figure IV).
Finally, we tested whether the lack of effect on inflammation, apoptosis, and efferocytosis seen in the hemato-
poietic cell -Axl deficient mice was due to a compensatory effect of increased expression of other TAM family 
members, namely, MerTK and Tyro3 in macrophages. However, immunostaining demonstrated that the expres-
sion levels of MerTK in the Axl−/− lesional macrophages was similar to WT (Supplementary Figure VA). The 
expression levels of Tyro3 on lesional macrophages was very low but similar between WT and BM-Axl−/− mice 
(Supplementary Figure VB). Also, the loss of Axl did not result in a compensatory increase in efferocytosis 
(Fig. 3A) or Gas6-mediated pAKT signaling (Fig. 3B) through Mertk and Tyro3 in bone-marrow derived mac-
rophages. These combined data show that Axl expression in bone marrow-derived cells does not play a major role 
in affecting the progression of advanced atherosclerotic lesions in WD-fed Ldlr−/− mice.
Discussion
Identifying the molecular-cellular processes involved in advanced atherosclerotic lesion progression is critical 
for understanding how clinically important plaques form and how their development may be therapeutically 
suppressed. In this context, TAM receptors, particularly MerTK and Axl, are of interest because of their expres-
sion in lesional cells and their involvement in both efferocytosis and inflammation control4–7,11, both of which go 
awry in advanced atherosclerosis. While previous studies have clearly demonstrated a protective role for MerTK 
in advanced atherosclerosis6,7, including in a bone-marrow chimera model7 similar to that used in this study, the 
role of Axl was not known. Our data showing that Axl deficiency in bone marrow-derived cells does not affect the 
most important parameters of advanced atherosclerosis is quite surprising and cannot be explained by compen-
satory up-regulation of MerTK or Tyro3. These findings are in contrast to a protective effect of holo-deficiency 
of Axl in intima media thickening (IMT) induced by partial ligation of carotid artery in mice13. The differences 
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could be due to the dominant role of endothelial and smooth muscle cells in the pathogenesis of injury-induced 
IMT in contrast to the major role of myeloid cells in the pathogenesis of classical atherosclerosis. Whether Axl 
signaling in endothelial and smooth muscle cells play a role in atherosclerosis progression will require a future 
study. However, it is important to note that human genetic studies have revealed that SNPs in Gas6 and Axl are 
not associated with carotid atherosclerosis14.
In the present study, our focus was predominantly on understanding the role of Axl expressed on 
hematopoietic-derived cells in advanced atherosclerosis and thus we chose to use the Axl−/− bone marrow chi-
mera model. Ldlr−/− mice are used for bone marrow transplant studies, because reconstitution of Apoe+/+ donors 
into Apoe−/− recipients results in lowering of cholesterol levels and suppression of atherosclerosis15. In addition, 
atherosclerosis in Western diet-fed Ldlr−/− mice is driven by LDL, as in humans, and this model also avoids 
Figure 1. Hematopoietic cell-Axl deficiency does not affect advanced atherosclerosis progression.  
(A) Representative images of H&E-stained aortic root sections from WT → Ldlr−/− or Axl−/− → Ldlr−/− mice 
fed the WD for 17 weeks. Bar, 200 μ m. (B,C) Quantification of total atherosclerotic lesion area and necrotic area 
in the two groups of mice. (D) Quantification of cellular distribution in atherosclerotic lesions as characterized 
by immunostaining for F4/80 (macrophages, Mφ ), CD11c (dendritic cells, DC), and a-smooth muscle 
actin (smooth muscle cells, SMC). (E) Quantification of collagen content and cap thickness in the intima of 
atherosclerotic lesions by Masson trichrome staining. n = 9 mice per group. Mann-Whitney test was conducted 
to determine statistical significance between the two groups. ns, no significant difference.
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the confounding effect of basal apolipoprotein E in various immune cells, which could impact atherosclerosis 
progression16–18.
Consistent with a previous report showing that Axl is induced by treatment of cultured macrophages with 
inflammatory stimuli8, we found that macrophages in inflammatory advanced atherosclerotic lesions express 
Axl. That report also showed that efferocytosis is partially defective in bone marrow-derived macrophages iso-
lated from Axl−/− mice and that mice treated with an Axl-activating antibody have a suppressed response to 
LPS in vivo8. In contrast, efferocytosis and inflammation were similar in the advanced atherosclerotic lesions of 
Axl−/− → Ldlr−/− and WT → Ldlr−/− mice. This finding, combined with previous reports showing that MerTK 
deficiency affects both efferocytosis and inflammation in lesions6,7 suggests that MerTK is the dominant TAM 
receptor in these processes in the setting of atherosclerosis. The mechanism for MerTK dominance remains to 
be elucidated and could in theory be related to differences in the expression levels of the two receptors and/
or in downstream signaling mechanisms. In addition, if the TAM receptor ligand Protein S were particularly 
important in advanced atherosclerosis, the finding that Protein S has a greater affinity for MerTK versus Axl may 
help explain the dominance of MerTK in this setting19. In the context of these possibilities, a study showed that 
advanced human carotid arteries were enriched in MerTK when compared with normal carotid arteries and that 
Protein S levels increased with advanced plaque grade20. While both Axl and Mertk are considered to be involved 
in efferocytosis and suppression of inflammation, a recent report raises the possibility that they may play oppos-
ing roles in certain inflammatory settings, such as that seen in a mouse model of nephrotoxic serum-induced 
glomerulonephritis21. Because that study was conducted using holo-Axl KO and holo-Mertk KO, the specific cell 
types that are responsible for these opposing effects remain to be elucidated.
In summary, in stark contrast to the findings with MerTK deficiency6,7, hematopoietic cell-Axl deficiency in 
WD-fed Ldlr−/− mice does not affect the progression of advanced atherosclerosis or lesional processes associ-
ated with TAM receptor signaling. These findings suggest a heretofore unappreciated TAM receptor functional 
Figure 2. Hematopoietic cell-Axl deficiency does not affect advanced atherosclerosis apoptosis, 
efferocytosis, or inflammatory gene expression. (A) Fluorescence microscopy-based quantification of 
TUNEL+ cells as a percentage of total lesional cells in WT → Ldlr−/− or Axl−/− → Ldlr−/− mice fed the WD for 
17 weeks. (B) In-situ efferocytosis analysis of aortic root sections; the ratio of macrophage-associated TUNEL+ 
cells to free TUNEL+ cells is a measure of lesional efferocytosis. (C) Quantitative RT-PCR for the indicated 
lesional mRNAs. n = 9 mice per group. Mann-Whitney test was conducted to determine statistical significance 
between the groups. ns, no significant difference.
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hierarchy in advanced atherosclerosis. Although the mechanistic basis for this hierarchy and its implications for 
atherosclerotic heart disease remain to be explored, the data highlight new issues related to the biology of these 
receptors in an actual disease setting driven by chronic, maladaptive inflammation.
Materials and Methods
Animals, bone marrow transplantation, and diet. Axl−/− mice on a C57BL6 background (11 back-
crosses) were bred and maintained in the animal facility at Columbia University. 8 week old female Ldlr−/− 
mice (Stock # 002207) were purchased from Jackson laboratories. Ldlr−/− mice were lethally irradiated (10 Gy) 
and transplanted with bone marrow cells isolated from either Axl−/− or WT littermate control mice. 6 weeks 
post-transplantation, the mice were fed the Western type diet ab libitum (TD88137, Teklad Diets, Envigo) for 17 
weeks. All animal experiments were conducted following relevant guidelines and regulations and approved by the 
Institutional Animal Care and Use Committee of Columbia University.
Metabolic parameter measurements. Animals were weighed weekly and the weights recorded. For 
measurements of plasma glucose and insulin, the mice were fasted for 5 hours before blood draw. Plasma glucose 
was measured using glucose test strips (Accu-Chek) and standard glucometer. Plasma insulin was measured 
using ELISA (Crystal Chem). Plasma cholesterol was measured using Cholesterol E kit (Wako) following manu-
facturer’s instructions.
Figure 3. Axl deficiency is not compensated functionally by Mertk expression. (A) WT and Axl−/− BMDMs 
were transfected with either negative control siRNA or Mertk siRNA as indicated. 48 h post-transfection, these 
macrophages were incubated with fluorescently-labeled apoptotic jurkat cells at a ratio of 1:10 for 60 min. 
Percent efferocytosis was analyzed by fluorescence microscopy. *p < 0.05 by ANOVA and Turkey’s multiple 
comparison test. The bar graph on the right demonstrates the efficiency of siRNA mediated knockdown of 
Mertk in BMDMs as determined by real-time PCR. *p < 0.05 by Student’s t-test. (B) WT and Axl−/− BMDM 
were treated with cell culture supernatants of γ -carboxyated human Gas-6-expressing HEK293-6E cells 
(Gas6) or supernatants from control HEK293-6E cells (Veh) for 30 min as indicated. Whole cell lysates were 
immunblotted for phospho-AKT. The bar graph represents densitometric quantification of the immunoblot 
normalized to the expression of β -actin. The data were derived from triplicates of the experiment. *p < 0.05 by 
ANOVA and multiple comparison test.
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Atherosclerotic lesion measurements. Aortic root atherosclerotic sections were stained with hema-
toxylin and eosin and total lesion area and necrotic area were measured by a person blinded to the groups as 
described previously6. Briefly, using ImageProPlus, the total intimal area from 6 sections per mouse was measured 
to arrive at the total lesion area. For necrotic area measurements, boundary lines were drawn around areas lacking 
hematoxylin-stained nuclei (acellular), which were then quantified using a 3,000-μ m2 threshold to avoid includ-
ing regions that did not represent substantial areas of necrosis. To measure collagen content of the lesions, 3 sec-
tions per mouse were stained with Masson’s trichrome stain following manufacturer’s instructions. An electronic 
color threshold was applied on the blue stained regions of the plaque (collagen) using ImageJ, and the percent 
collagen positive area was then determined.
TUNEL, immunostaining, and in-situ efferocytosis assay. Lesional cell apoptosis was measured by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay using TMR red in-situ cell death 
detection kit (Roche) following manufacturer’s instructions. The TUNEL stained aortic root sections were imaged 
under a fluorescence microscope and quantification was conducted using ImageJ image analysis software. In-situ 
efferocytosis assay was conducted as described previously6. Briefly, aortic root sections were stained with TUNEL 
followed by immunostaining for macrophages using anti-F4/80 antibody (AbD Serotech). Lesional efferocytosis was 
evaluated by counting the number of free versus macrophage-associated TUNEL+ cells in atherosclerotic lesional 
sections. Apoptotic cells were considered “free” when they were not surrounded by or in contact with macrophages.
mRNA isolation and real-time PCR. Aortic root sections were lysed in RLT buffer containing 
β -mercaptoethanol following which RNA was isolated using RNeasy Micro kit (Qiagen). cDNA was generated 
from the isolated mRNA using Superscript Vilo cDNA synthesis kit. Gene expression analysis was conducted by 
quantitative real time PCR (Applied Biosystems 7500 RTPCR machine) using SYBR green probe. The following 
primers were used in this study: TNF-α (5′-CATCTTCTCAAAATTCGAGTGACAA-3′ /5′-TGGGAGTAGA 
CAAGGTACAACCC-3′ ); IL-12 p40 (5′ -CCTGCATCTAGAGGCTGTCC-3′ /5′ -GGCAAACCAGGAGAT 
GGTTA-3′ ); MCP-1 (5′-CCCCACTCACCTGCTGCTACT-3′ /5′-TTTACGGGTCAACTTGACATTC-3′ ); 
Mertk (5′ -GTGGCAGTGAAGACCATGAAGTTG-3′ /5′ -GAACTCCGGGATAGGGAGTCAT-3′ ). The primers 
for IL-6, IFN-γ , and IL-23 were obtained from Qiagen.
Statistics. The data presented in this manuscript are represented as means ± SEM. The n numbers for each 
group are indicated in the figure legends. The statistical test conducted to determine significance for each experi-
ment is indicated in the figure legends. A p-value of < 0.05 was considered as statistically significant.
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